Skip to main content

June 2018, Vol 8, No 6

The combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) extended progression-free survival (PFS) versus standard chemotherapy as first-line treatment for patients with advanced non–small-cell lung cancer (NSCLC) and a high tumor mutational burden (TMB). This finding was unrelated to levels of PD-L1 expression, said Matthew D. Hellmann, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York City. Read More ›

Oncology practices, hospitals, and pharmacies are struggling to understand wide variations in the application of sterile compounding and safe handling of oncology hazardous drugs, and the costs and operating burdens of compliance with and adherence to current pharmacy standards. At the 2018 combined meeting of the Association of Community Cancer Centers and the Cancer Center Business Summit, 3 cancer centers shared their stories and experiences related to pharmacy standards compliance. Read More ›

Many cancer survivors do not meet general recommendations for diet and exercise because of a multitude of common barriers, according to Erin Van Blarigan, ScD, Assistant Professor, Departments of Epidemiology & Biostatistics and Urology, University of California, San Francisco. Read More ›

Page 2 of 2